Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

Brigitta G. Baumert; Monika E. Hegi; Martin J. van den Bent; Andreas von Deimling; Thierry Gorlia; Khe Hoang-Xuan; Alba A. Brandes; Guy Kantor; Martin J. B. Taphoorn; Mohamed Ben Hassel; Christian Hartmann; Gail Ryan; David Capper; Johan M. Kros; Sebastian Kurscheid; Wolfgang Wick; Roelien Enting; Michele Reni; Brian Thiessen; Frederic Dhermain; Jacoline E. Bromberg; Loic Feuvret; Jaap C. Reijneveld; Olivier Chinot; Johanna M. M. Gijtenbeek; John P. Rossiter; Nicolas Dif; Carmen Balana; Jose Bravo-Marques; Paul M. Clement; Christine Marosi; Tzahala Tzuk-Shina; Robert A. Nordal; Jeremy Rees; Denis Lacombe; Warren P. Mason; Roger Stupp

doi:10.1016/S1470-2045(16)30313-8

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

Brigitta G. Baumert, Monika E. Hegi, Martin J. van den Bent, Andreas von Deimling, Thierry Gorlia, Khe Hoang-Xuan, Alba A. Brandes, Guy Kantor, Martin J. B. Taphoorn, Mohamed Ben Hassel, Christian Hartmann, Gail Ryan, David Capper, Johan M. Kros, Sebastian Kurscheid, Wolfgang Wick, Roelien Enting, Michele Reni, Brian Thiessen, Frederic DhermainJacoline E. Bromberg, Loic Feuvret, Jaap C. Reijneveld, Olivier Chinot, Johanna M. M. Gijtenbeek, John P. Rossiter, Nicolas Dif, Carmen Balana, Jose Bravo-Marques, Paul M. Clement, Christine Marosi, Tzahala Tzuk-Shina, Robert A. Nordal, Jeremy Rees, Denis Lacombe, Warren P. Mason, Roger Stupp

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	1521-1532
Journal	Lancet oncology
Volume	17
Issue number	11
DOIs	https://doi.org/10.1016/S1470-2045(16)30313-8
Publication status	Published - Nov 2016

Access to Document

10.1016/S1470-2045(16)30313-8

Cite this

Baumert, B. G., Hegi, M. E., van den Bent, M. J., von Deimling, A., Gorlia, T., Hoang-Xuan, K., Brandes, A. A., Kantor, G., Taphoorn, M. J. B., Ben Hassel, M., Hartmann, C., Ryan, G., Capper, D., Kros, J. M., Kurscheid, S., Wick, W., Enting, R., Reni, M., Thiessen, B., ... Stupp, R. (2016). Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet oncology, 17(11), 1521-1532. https://doi.org/10.1016/S1470-2045(16)30313-8

Baumert, Brigitta G. ; Hegi, Monika E. ; van den Bent, Martin J. ; von Deimling, Andreas ; Gorlia, Thierry ; Hoang-Xuan, Khe ; Brandes, Alba A. ; Kantor, Guy ; Taphoorn, Martin J. B. ; Ben Hassel, Mohamed ; Hartmann, Christian ; Ryan, Gail ; Capper, David ; Kros, Johan M. ; Kurscheid, Sebastian ; Wick, Wolfgang ; Enting, Roelien ; Reni, Michele ; Thiessen, Brian ; Dhermain, Frederic ; Bromberg, Jacoline E. ; Feuvret, Loic ; Reijneveld, Jaap C. ; Chinot, Olivier ; Gijtenbeek, Johanna M. M. ; Rossiter, John P. ; Dif, Nicolas ; Balana, Carmen ; Bravo-Marques, Jose ; Clement, Paul M. ; Marosi, Christine ; Tzuk-Shina, Tzahala ; Nordal, Robert A. ; Rees, Jeremy ; Lacombe, Denis ; Mason, Warren P. ; Stupp, Roger. / Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. In: Lancet oncology. 2016 ; Vol. 17, No. 11. pp. 1521-1532.

@article{154e5e16ec484ae98b01265f7c98e944,

title = "Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study",

author = "Baumert, {Brigitta G.} and Hegi, {Monika E.} and {van den Bent}, {Martin J.} and {von Deimling}, Andreas and Thierry Gorlia and Khe Hoang-Xuan and Brandes, {Alba A.} and Guy Kantor and Taphoorn, {Martin J. B.} and {Ben Hassel}, Mohamed and Christian Hartmann and Gail Ryan and David Capper and Kros, {Johan M.} and Sebastian Kurscheid and Wolfgang Wick and Roelien Enting and Michele Reni and Brian Thiessen and Frederic Dhermain and Bromberg, {Jacoline E.} and Loic Feuvret and Reijneveld, {Jaap C.} and Olivier Chinot and Gijtenbeek, {Johanna M. M.} and Rossiter, {John P.} and Nicolas Dif and Carmen Balana and Jose Bravo-Marques and Clement, {Paul M.} and Christine Marosi and Tzahala Tzuk-Shina and Nordal, {Robert A.} and Jeremy Rees and Denis Lacombe and Mason, {Warren P.} and Roger Stupp",

year = "2016",

month = nov,

doi = "10.1016/S1470-2045(16)30313-8",

language = "English",

volume = "17",

pages = "1521--1532",

journal = "Lancet oncology",

issn = "1470-2045",

publisher = "Elsevier Science",

number = "11",

}

Baumert, BG, Hegi, ME, van den Bent, MJ, von Deimling, A, Gorlia, T, Hoang-Xuan, K, Brandes, AA, Kantor, G, Taphoorn, MJB, Ben Hassel, M, Hartmann, C, Ryan, G, Capper, D, Kros, JM, Kurscheid, S, Wick, W, Enting, R, Reni, M, Thiessen, B, Dhermain, F, Bromberg, JE, Feuvret, L, Reijneveld, JC, Chinot, O, Gijtenbeek, JMM, Rossiter, JP, Dif, N, Balana, C, Bravo-Marques, J, Clement, PM, Marosi, C, Tzuk-Shina, T, Nordal, RA, Rees, J, Lacombe, D, Mason, WP & Stupp, R 2016, 'Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study', Lancet oncology, vol. 17, no. 11, pp. 1521-1532. https://doi.org/10.1016/S1470-2045(16)30313-8

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. / Baumert, Brigitta G.; Hegi, Monika E.; van den Bent, Martin J.; von Deimling, Andreas; Gorlia, Thierry; Hoang-Xuan, Khe; Brandes, Alba A.; Kantor, Guy; Taphoorn, Martin J. B.; Ben Hassel, Mohamed; Hartmann, Christian; Ryan, Gail; Capper, David; Kros, Johan M.; Kurscheid, Sebastian; Wick, Wolfgang; Enting, Roelien; Reni, Michele; Thiessen, Brian; Dhermain, Frederic; Bromberg, Jacoline E.; Feuvret, Loic; Reijneveld, Jaap C.; Chinot, Olivier; Gijtenbeek, Johanna M. M.; Rossiter, John P.; Dif, Nicolas; Balana, Carmen; Bravo-Marques, Jose; Clement, Paul M.; Marosi, Christine; Tzuk-Shina, Tzahala; Nordal, Robert A.; Rees, Jeremy; Lacombe, Denis; Mason, Warren P.; Stupp, Roger.

In: Lancet oncology, Vol. 17, No. 11, 11.2016, p. 1521-1532.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

AU - Baumert, Brigitta G.

AU - Hegi, Monika E.

AU - van den Bent, Martin J.

AU - von Deimling, Andreas

AU - Gorlia, Thierry

AU - Hoang-Xuan, Khe

AU - Brandes, Alba A.

AU - Kantor, Guy

AU - Taphoorn, Martin J. B.

AU - Ben Hassel, Mohamed

AU - Hartmann, Christian

AU - Ryan, Gail

AU - Capper, David

AU - Kros, Johan M.

AU - Kurscheid, Sebastian

AU - Wick, Wolfgang

AU - Enting, Roelien

AU - Reni, Michele

AU - Thiessen, Brian

AU - Dhermain, Frederic

AU - Bromberg, Jacoline E.

AU - Feuvret, Loic

AU - Reijneveld, Jaap C.

AU - Chinot, Olivier

AU - Gijtenbeek, Johanna M. M.

AU - Rossiter, John P.

AU - Dif, Nicolas

AU - Balana, Carmen

AU - Bravo-Marques, Jose

AU - Clement, Paul M.

AU - Marosi, Christine

AU - Tzuk-Shina, Tzahala

AU - Nordal, Robert A.

AU - Rees, Jeremy

AU - Lacombe, Denis

AU - Mason, Warren P.

AU - Stupp, Roger

PY - 2016/11

Y1 - 2016/11

U2 - 10.1016/S1470-2045(16)30313-8

DO - 10.1016/S1470-2045(16)30313-8

M3 - Article

VL - 17

SP - 1521

EP - 1532

JO - Lancet oncology

JF - Lancet oncology

SN - 1470-2045

IS - 11

ER -